Abstract:Background The diagnostic value of screening the contralateral breast with MRI in patients with newly diagnosed breast cancer is poorly understood. Purpose To assess the impact of MRI for screening the contralateral breast on long-term outcomes in patients with newly diagnosed breast cancer and to determine whether subgroups with unfavorable prognoses would benefit from MRI in terms of survival. Materials and Methods Data on consecutive patients with newly diagnosed breast cancer seen from January 2008 to December 2010 were reviewed retrospectively. Patients with neoadjuvant chemotherapy, previous breast cancer, distant metastasis, absence of contralateral mammography at diagnosis, and no planned surgical treatment were excluded. Groups that did and did not undergo preoperative MRI were compared. Survival analysis was performed using the Kaplan-Meier method for propensity score-matched groups to estimate cause-specific survival (CSS) and overall survival (OS). A marginal Cox proportional hazards model was used to evaluate association of MRI and clinicopathologic variables with OS. Results Of 1846 patients, 1199 fulfilled the inclusion criteria. Median follow-up time was 10 years (range, 0-14 years). The 2:1 matched sample comprised 705 patients (470 in the MRI group and 235 in the no-MRI group); median ages at surgery were 59 years (range, 31-87 years) and 64 years (range, 37-92 years), respectively. MRI depicted contralateral synchronous disease more frequently (27 of 470 patients [5.7%] vs five of 235 patients [2.1%]; = .047) and was associated with a higher OS (hazard ratio [HR], 2.51; 95% CI: 1.25, 5.06; = .01). No differences were observed between groups in metachronous disease rate (MRI group: 21 of 470 patients [4.5%]; no-MRI group: 10 of 235 patients [4.3%]; > .99) or CSS (HR, 1.34; 95% CI: 0.56, 3.21; = .51). MRI benefit was greater in patients with larger tumor sizes (>2 cm) (HR, 2.58; 95% CI: 1.11, 5.99; = .03) and histologic grade III tumors (HR, 2.94; 95% CI: 1.18, 7.32; = .02). Conclusion Routine MRI screening of the contralateral breast after first diagnosis of breast cancer improved overall survival; the most pronounced benefit was found in patients with larger primary tumor size and primary tumors of histologic grade III. © RSNA, 2022 See also the editorial by Taourel in this issue.

The Role of MRI in Breast Cancer and Breast Conservation Therapy

MRI for breast cancer screening, diagnosis, and treatment

Breast MRI for Evaluation of Response to Neoadjuvant Therapy

Breast MRI: Clinical Indications, Recommendations, and Future Applications in Breast Cancer Diagnosis

Clinical role of abbreviated and ultrafast mri in breast imaging

Screening Breast MRI Primer: Indications, Current Protocols, and Emerging Techniques

PET/MRI in Breast Cancer

The role of MRI in radiotherapy planning: a narrative review "from head to toe"

Beyond imaging: a systematic exploration of radiomics in breast cancer diagnosis and treatment assessment

A Concise Review on the Utilization of Abbreviated Protocol Breast MRI over Full Diagnostic Protocol in Breast Cancer Detection

Magnetic Resonance Perfusion Imaging for Breast Cancer

Contralateral Breast Screening with Preoperative MRI: Long-Term Outcomes for Newly Diagnosed Breast Cancer

Role of Radiology in the Diagnosis and Treatment of Breast Cancer in Women: A Comprehensive Review

Preoperative Breast MRI for Early-Stage Breast Cancer: Effect on Surgical and Long-Term Outcomes

MRI is Not Exclusive for Breast Cancer Imaging Diagnostics

New Trends of MRI in Breast Cancer Diagnosis

Diagnosis and Staging of Breast Cancer: When and How to Use Mammography, Tomosynthesis, Ultrasound, Contrast-Enhanced Mammography, and Magnetic Resonance Imaging

Contrast-Enhanced Mammogram: A New Game-Changer in Breast Imaging. Indications with Case-Based Experience

PET/MRI and Novel Targets for Breast Cancer

Contrast-enhanced breast imaging: Current status and future challenges

The Use of Magnetic Resonance Imaging in Radiation Therapy Treatment Simulation and Planning